|
1
|
Ekberg M, Callender M, Hamer H and Rogers
S: Exploring the decision to participate in the national health
service bowel cancer screening programme. Eur J Cancer Prev.
23:391–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hou L, Jiang J, Liu B, Nasca PC, Wu Y, Zou
X, Han W, Chen Y, Zhang B, Xue F, et al: Association between
smoking and deaths due to colorectal malignant carcinoma: a
national population-based case-control study in China. Br J Cancer.
110:1351–1358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chatenoud L, Bertuccio P, Bosetti C,
Malvezzi M, Levi F, Negri E and La Vecchia C: Trends in mortality
from major cancers in the Americas: 1980–2010. Ann Oncol.
25:1843–1853. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zaniboni A and Labianca R: Gruppo Italiano
per lo Studio e la Cura dei Tumori del Digerente: Adjuvant therapy
for stage II colon cancer: an elephant in the living room? Ann
Oncol. 15:1310–1318. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rao S and Cunningham D: Adjuvant therapy
for colon cancer in the new millenium. Scand J Surg. 92:57–64.
2003.PubMed/NCBI
|
|
7
|
Sinha VR and Honey C: Critical aspects in
rationale design of fluorouracil-based adjuvant therapies for the
management of colon cancer. Crit Rev Ther Drug Carrier Syst.
29:89–148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lotfi-Jam K, Carey M, Jefford M, Schofield
P, Charleson C and Aranda S: Nonpharmacologic strategies for
managing common chemotherapy adverse effects: a systematic review.
J Clin Oncol. 26:5618–5629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Latimer N, Lord J, Grant RL, O'Mahony R,
Dickson J and Conaghan PG: Value of information in the
osteoarthritis setting: Cost effectiveness of COX-2 selective
inhibitors, traditional NSAIDs and proton pump inhibitors.
Pharmacoeconomics. 29:225–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jacobo-Herrera NJ, Pérez-Plasencia C,
Camacho-Zavala E, González GF, Urrutia EL, García-Castillo V and
Zentella-Dehesa A: Clinical evidence of the relationship between
aspirin and breast cancer risk (review). Oncol Rep.
32:4512014.PubMed/NCBI
|
|
11
|
Brasky TM, Liu J, White E, et al:
Non-steroidal anti-inflammatory drugs and cancer risk in women:
results from the Women's Health Initiative. Int J Cancer.
135:1869–1883. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu X, Cai M, Ji F and Lou LM: The impact
of COX-2 on invasion of osteosarcoma cell and its mechanism of
regulation. Cancer Cell Int. 14:272014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liggett JL, Zhang X, Eling TE and Baek SJ:
Anti-tumor activity of non-steroidal anti-inflammatory drugs:
cyclooxygenase-independent targets. Cancer Lett. 346:217–224. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davies NM and Jamali F: COX-2 selective
inhibitors cardiac toxicity: getting to the heart of the matter. J
Pharm Pharm Sci. 7:332–336. 2004.PubMed/NCBI
|
|
15
|
Zhang MF, Zhao Y, Jiang KY, et al:
Comparative pharmacokinetics study of sinomenine in rats after oral
dministration of sinomenine monomer and sinomenium acutum extract.
Molecules. 19:12065–12077. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao T, Hao J, Wiesenfeld-Hallin Z, et al:
Analgesic effect of sinomenine in rodents after inflammation and
nerve injury. Eur J Pharmacol. 721:5–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mo ZX, An SL and Zhou JY: Effects of
caulis sinomenii and sinomenine on morphine-induced place
preference and brain histamine level in mice. Nan Fang Yi Ke Da Xue
Xue Bao. 26:1709–1713. 2006.(In Chinese). PubMed/NCBI
|
|
18
|
Yamasaki H: Pharmacology of sinomenine, an
anti-rheumatic alkaloid from sinomenium acutum. Acta Med Okayama.
30:1–20. 1976.PubMed/NCBI
|
|
19
|
Candinas D, Mark W, Kaever V, et al:
Immunomodulatory effects of the alkaloid sinomenine in the high
responder ACI-to-Lewis cardiac allograft model. Transplantation.
62:1855–1860. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang T, Zhou L, Zhang W, Qu D, Xu X, Yang
Y and Li S: Effects of sinomenine on proliferation and apoptosis in
human lung cancer cell line NCI-H460 in vitro. Mol Med Rep.
3:51–56. 2010.PubMed/NCBI
|
|
21
|
Zhou L, Luan H, Liu Q, Jiang T, Liang H,
Dong X and Shang H: Activation of PI3K/Akt and ERK signaling
pathways antagonized sinomenine-induced lung cancer cell apoptosis.
Mol Med Rep. 5:1256–1260. 2012.PubMed/NCBI
|
|
22
|
Kues WA, Anger M, Carnwath JW, et al: Cell
cycle synchronization of porcine fetal fibroblasts: effects of
serum deprivation and reversible cell cycle inhibitors. Biol
Reprod. 62:412–419. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen M, Huang J, Yang X, et al: Serum
starvation induced cell cycle synchronization facilitates human
somatic cells reprogramming. PLoS One. 7:e282032012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tan Y, Sun X, Xu M, et al: Efficacy of
recombinant methioninase in combination with cisplatin on human
colon tumors in nude mice. Clin Cancer Res. 5:2157–2163.
1999.PubMed/NCBI
|
|
25
|
Tjandrawinata RR, Dahiya R and
Hughes-Fulford M: Induction of cyclo-oxygenase-2 mRNA by
prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer.
75:1111–1118. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maekawa M, Sugano K, Sano H, et al:
Increased expression of cyclooxygenase-2 to −1 in human colorectal
cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin
Oncol. 28:421–426. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hao X, Bishop AE, Wallace M, et al: Early
expression of cyclo-oxygenase-2 during sporadic colorectal
carcinogenesis. J Pathol. 187:295–301. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sheehan KM, Sheahan K, O'Donoghue DP,
MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The
relationship between cyclooxygenase-2 expression and colorectal
cancer. JAMA. 282:1254–1257. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kõivomägi M and Skotheim JM: Docking
interactions: cell-cycle regulation and beyond. Curr Biol.
24:R647–R649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dorée M and Hunt T: From Cdc2 to Cdk1:
when did the cell cycle kinase join its cyclin partner? J Cell Sci.
115:2461–2464. 2002.PubMed/NCBI
|
|
31
|
Sherr CJ and Roberts JM: Living with or
without cyclins and cyclin-dependent kinases. Genes Dev.
18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fisher D, Krasinska L, Coudreuse D and
Novák B: Phosphorylation network dynamics in the control of cell
cycle transitions. J Cell Sci. 125:4703–4711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoon MK, Mitrea DM, Ou L and Kriwacki RW:
Cell cycle regulation by the intrinsically disordered proteins p21
and p27. Biochem Soc Trans. 40:981–988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weinberg WC and Denning MF: P21Waf1
control of epithelial cell cycle and cell fate. Crit Rev Oral Biol
Med. 13:453–464. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shankland SJ and Wolf G: Cell cycle
regulatory proteins in renal disease: Role in hypertrophy,
proliferation and apoptosis. Am J Physiol Renal Physiol.
278:F515–F529. 2000.PubMed/NCBI
|
|
36
|
Todd R, Hinds PW, Munger K, Rustgi AK,
Opitz OG, Suliman Y and Wong DT: Cell cycle dysregulation in oral
cancer. Crit Rev Oral Bio Med. 13:51–61. 2002. View Article : Google Scholar
|
|
37
|
Schafer KA: The cell cycle: a review. Vet
Pathol. 35:461–478. 1998. View Article : Google Scholar : PubMed/NCBI
|
